

CLL

# SPARK

WHAT'S POSSIBLE  
WITH JAYPIRCA® (PIRTOBRUTINIB)

## Indication

Jaypirca is a prescription medicine used to treat adults with **chronic lymphocytic leukemia (CLL)** or **small lymphocytic lymphoma (SLL)** that has come back or did not respond to previous treatment and who have already been treated with a BTK inhibitor for their cancer.

It is not known if Jaypirca is safe and effective in children.

BTK=Bruton tyrosine kinase.

## Select Important Safety Information

**Warnings - Jaypirca may cause serious side effects, including:**

**Infections.** Infections can happen during treatment with Jaypirca. These infections can be serious and may lead to death. Your doctor may prescribe vaccines and certain medicines if you have an increased risk of getting infections. Tell your doctor right away if you have fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with Jaypirca.

Please see **Safety Summary** for Jaypirca on pages 10-12.

KEEP READING TO LEARN  
MORE ABOUT JAYPIRCA

Not an actual patient.

**Jaypirca**®  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

# What is Jaypirca?

Jaypirca is a prescription medicine used to treat adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has come back or did not respond to previous treatment and who have already received a BTK inhibitor for their cancer.

You may have taken BTK inhibitors before. BTK inhibitors stop, or inhibit, cancer cells from surviving and multiplying, which can slow the spread of certain cancers like CLL.

**Jaypirca, a noncovalent BTK inhibitor, works differently than other BTK inhibitors you may have taken before.**

For CLL, it was developed to work after you have taken a covalent BTK inhibitor.



Not an actual patient.

## Select Important Safety Information

**Warnings - Jaypirca may cause serious side effects, including:**

**Bleeding problems (hemorrhage).** Bleeding problems can happen during treatment with Jaypirca.

They can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your doctor if you have any signs or symptoms of bleeding, including:

- blood in your stools or black stools (looks like tar)
- pink or brown urine
- unexpected bleeding, or bleeding that is severe or you cannot control
- vomit blood or vomit blood that looks like coffee grinds
- cough up blood or blood clots
- increased bruising
- dizziness
- weakness
- confusion
- changes in your speech
- headache that lasts a long time



**Jaypirca**<sup>®</sup>  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

# How to take Jaypirca

Take Jaypirca exactly as your healthcare provider tells you



Not an actual patient.



## How do I take Jaypirca?

Take Jaypirca 1 time each day, at about the same time each day. Take Jaypirca with or without food. Swallow Jaypirca whole with water. Do not cut, crush, or chew the tablets.



## What if I miss a dose?

If you miss a dose of Jaypirca, take it as soon as you remember on the same day. If it has been more than 12 hours, skip the missed dose and take your next dose on the next day at your usual time.



## What if I experience side effects?

Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking Jaypirca if you develop side effects. Do not change your dose or stop taking Jaypirca without talking to your healthcare provider first.

## Select Important Safety Information

**Warnings - Jaypirca may cause serious side effects, including:**

**Decrease in blood cell counts.** Decrease in white blood cells, platelets, and red blood cells are common with Jaypirca, but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your doctor should do blood tests regularly during treatment to monitor your counts.

 **Jaypirca**<sup>®</sup>  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

# Understanding how Jaypirca was studied in CLL

Jaypirca was studied in 2 different clinical trials in people with CLL/SLL. In the more recent trial, Jaypirca was compared with 2 other possible treatments. The primary measure of this trial was how long people lived without their disease getting worse (progression-free survival). In the earlier trial, Jaypirca was studied alone. The primary measure of that trial was the percentage of people who responded to treatment with Jaypirca. (A response means their cancer shrank and stopped spreading.) This study also measured how long those responses lasted.

## CLINICAL TRIAL OF JAYPIRCA AGAINST 2 POSSIBLE TREATMENTS\*



### Jaypirca was studied in 238 adults with relapsed or refractory<sup>†</sup> CLL

- All people in the study had already received a covalent BTK inhibitor
- The trial measured how long people lived without their CLL getting worse (progression-free survival)
- The people in the trial were randomly assigned to receive either Jaypirca (119 people) or 1 of 2 other CLL treatment combinations (119 people)\*
- People who were assigned to receive Jaypirca took it until their CLL got worse or they were no longer able to tolerate treatment

\*These combinations were idelalisib plus rituximab or bendamustine plus rituximab.

<sup>†</sup>Refractory is when your cancer doesn't respond to treatment.

## CLINICAL TRIAL OF JAYPIRCA STUDIED ALONE



### Jaypirca was studied in 108 adults with previously treated CLL

- All people in the study had received at least 2 prior treatments, including a BTK inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor
- The trial evaluated participants on their response to treatment (a response means their cancer shrank and stopped spreading) and how long the response lasted
- People in the trial took Jaypirca once daily until their disease got worse or they were no longer able to tolerate treatment

## Select Important Safety Information

### Warnings - Jaypirca may cause serious side effects, including:

**Heart rhythm problems.** Heart rhythm problems including atrial fibrillation and atrial flutter have happened in people treated with Jaypirca. Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. Tell your doctor if you have any of the following symptoms:

- fast or irregular heartbeat
- fainting
- (palpitations)
- chest discomfort
- dizziness
- shortness of breath



**Jaypirca**<sup>®</sup>  
pirtobrutinib 50,100 mg  
tablets

A Lilly Medicine

# Results for Jaypirca from 2 clinical trials in CLL

## CLINICAL TRIAL OF JAYPIRCA AGAINST 2 OTHER TREATMENTS

### In the primary analysis, Jaypirca delayed CLL progression longer

The trial measured progression-free survival (how long patients lived without their CLL getting worse) in 119 people who were assigned to take Jaypirca and 119 people who were assigned to take another treatment.

### Primary Analysis: Median<sup>a</sup> Progression-Free Survival (median follow-up of 6.6 months)



### Updated Analysis: Median<sup>a</sup> Progression-Free Survival (median study follow-up of 17.2 months)



The data collected in the updated analysis of progression-free survival are from an unplanned look at the data that used less rigorous testing. This means the findings are less certain and may be due to chance.

<sup>a</sup>Median is the middle number in a range of numbers.

CONTINUED ↓

### Select Important Safety Information

**Warnings - Jaypirca may cause serious side effects, including:**

**Second primary cancers.** New cancers have happened during treatment with Jaypirca, including cancers of the skin or other organs. Your doctor will check you for other cancers during treatment. Use sun protection when you are outside in sunlight.



**Jaypirca**<sup>®</sup>  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

# Results for Jaypirca from 2 clinical trials in CLL (cont'd)

## CLINICAL TRIAL OF JAYPIRCA STUDIED ALONE

**Most adults with CLL who took Jaypirca saw their cancer shrink and stop spreading**

**In a clinical trial that measured the number of people who responded to treatment and how long the response lasted:**



of adults with CLL (78 out of 108) saw their **cancer shrink and stop spreading** while taking Jaypirca

For those who saw their CLL shrink and stop spreading, their response lasted a median\* of 12.2 months.

\*Median is the middle number in a range of numbers.

## Select Important Safety Information

**Warnings - Jaypirca may cause serious side effects, including:**

**Liver Problems.** Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with Jaypirca. Your doctor will do blood tests to check your liver before and during treatment with Jaypirca. Tell your doctor or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

Your doctor may decrease your dose, temporarily stop, or permanently stop treatment with Jaypirca if you develop severe side effects.



**Jaypirca**<sup>®</sup>  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

# Understanding the **possible side effects of Jaypirca**

## Jaypirca can cause serious side effects, including:

- Infections
- Bleeding problems (hemorrhage)
- Decrease in blood counts (white blood cells, platelets, and red blood cells)
- Heart rhythm problems (atrial fibrillation and atrial flutter)
- Second primary cancers (new cancers, including of the skin or other organs)
- Liver problems


These are not all the possible side effects of Jaypirca. See accompanying Safety Summary for more information.

If you experience side effects while on treatment, it's important to talk to your doctor.

## The most common side effects of Jaypirca include:

- Decreased white blood cell count
- Decreased red blood cell count
- Tiredness
- Decreased platelet count
- Decreased calcium

## IN A CLINICAL TRIAL THAT COMPARED JAYPIRCA WITH 2 OTHER TREATMENTS



### **83% of people with CLL kept taking Jaypirca without needing to stop treatment due to side effects.**

- 17% of **people with CLL** (20 out of 116) stopped taking Jaypirca permanently due to side effects
- Side effects that caused more than 1% of patients to permanently stop taking Jaypirca included pneumonia, COVID-19, COVID-19 pneumonia, low white blood cell count, and low red blood cell count

 **Jaypirca**<sup>®</sup>  
pirtobrutinib 50,100 mg  
tablets

# See how you may be able to **save** on **Jaypirca**



## Jaypirca Savings Card

Paying for treatment shouldn't be an additional concern for you and your loved ones, so we've created the Jaypirca Savings Card for eligible, commercially insured patients, which may help you manage treatment costs

Eligible, commercially insured covered patients pay as little as \$0 a month.\*

\*Month is defined as 30-days.

**Governmental beneficiaries excluded, terms and conditions apply.**

Need a Jaypirca Savings Card? Visit [www.jaypirca.lilly.com/savings-support#savings](http://www.jaypirca.lilly.com/savings-support#savings) for more information or call the Jaypirca Savings Card Support Line at 1-833-727-4589

By enrolling in and using the Jaypirca Savings Card Program ("Program") and using the Jaypirca Savings Card ("Card"), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

### **Card Eligibility:**

- (1.) You have been prescribed Jaypirca® (pirtobrutinib) for an approved use consistent with FDA-approved product labeling;
- (2.) You are enrolled in a commercial drug insurance plan and have coverage for Jaypirca;
- (3.) **You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;**
- (4.) You are a resident of the United States or Puerto Rico; and
- (5.) You are 18 years of age or older.

### **Card Terms and Conditions**

For patients with commercial drug insurance coverage for Jaypirca: You must have commercial drug insurance that covers Jaypirca and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as \$0 for a 1-month prescription fill of Jaypirca. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to \$10,600 per calendar year. Card may be used for a maximum of up to 14 prescription fills per calendar year. Except where prohibited by applicable state law, Card monthly and annual savings are reduced if Lilly identifies that you are enrolled in a plan or program, sometimes called a maximizer plan, that adjusts your cost sharing amount to be equal to or include some portion of the savings provided by the Card and attempts to prevent the savings from this Card from being applied to your out-of-pocket costs, including but not limited to copayments, coinsurances, and deductibles ("Maximizer"). If the Program identifies you are enrolled in a Maximizer, Card savings are reduced to a maximum monthly savings of up to \$25 and a separate maximum annual savings of up to \$350 per calendar year. If you have reason to believe that the Program erroneously identified enrollment in a Maximizer, please call the Jaypirca Savings Card Program at 1-833-727-4589. Subject to Lilly USA, LLC's ("Lilly") right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

### **Additional Program Terms and Conditions**

If you have an insurance plan that is participating in an alternate funding program ("AFP") that requires you to apply to the Jaypirca Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for,

**CONTINUED** ↓



**Jaypirca**®  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

# Savings & Support

## Additional Program Terms and Conditions (cont'd)

or prerequisite to coverage of Jaypirca, you are not eligible for and are prohibited from using the Jaypirca Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Jaypirca Savings Card Program. You agree to inform the Jaypirca Savings Card Program if you are or become a member of such an AFP. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Jaypirca, only allows partial coverage for Jaypirca, removes coverage for Jaypirca and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Jaypirca, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Jaypirca. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Jaypirca Savings Card and agree to call the Jaypirca Savings Card Program at 1-833-727-4589 to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Jaypirca. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. **THIS CARD IS NOT INSURANCE.** Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly's sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card's eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Jaypirca Savings Card Program may change from time to time; the most current version can be found at <https://www.jaypirca.lilly.com/savings-support#savings>. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.



### Questions about savings?

Call the Jaypirca Savings Card Support Line at **1-833-727-4589**.

For all other questions regarding support, call Lilly Support Services™ at **1-800-LillyRx (1-800-545-5979)**.

For more information, visit **[jaypirca.lilly.com/savings-support](https://www.jaypirca.lilly.com/savings-support)**. Jaypirca support program and offerings are not a guarantee of coverage. Terms and conditions apply for all programs.



**Jaypirca**<sup>®</sup>  
pirtobrutinib 50,100 mg  
tablets

A Lilly Medicine

# Safety Summary

## Warnings - Jaypirca may cause serious side effects, including:

**Infections.** Infections can happen during treatment with Jaypirca. These infections can be serious and may lead to death. Your doctor may prescribe vaccines and certain medicines if you have an increased risk of getting infections. Tell your doctor right away if you have fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with Jaypirca.

**Bleeding problems (hemorrhage).** Bleeding problems can happen during treatment with Jaypirca. They can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your doctor if you have any signs or symptoms of bleeding, including:

- blood in your stools or black stools (looks like tar)
- pink or brown urine
- unexpected bleeding, or bleeding that is severe or you cannot control
- vomit blood or vomit blood that looks like coffee grinds
- cough up blood or blood clots
- increased bruising
- dizziness
- weakness
- confusion
- changes in your speech
- headache that lasts a long time

**Decrease in blood cell counts.** Decrease in white blood cells, platelets, and red blood cells are common with Jaypirca, but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your doctor should do blood tests regularly during treatment to monitor your counts.

**Heart rhythm problems.** Heart rhythm problems including atrial fibrillation and atrial flutter have happened in people treated with Jaypirca. Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. Tell your doctor if you have any of the following symptoms:

- fast or irregular heartbeat (palpitations)
- dizziness
- fainting
- chest discomfort
- shortness of breath

**Second primary cancers.** New cancers have happened during treatment with Jaypirca, including cancers of the skin or other organs. Your doctor will check you for other cancers during treatment. Use sun protection when you are outside in sunlight.

**Liver Problems.** Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with Jaypirca. Your doctor will do blood tests to check your liver before and during treatment with Jaypirca. Tell your doctor or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

Your doctor may decrease your dose, temporarily stop, or permanently stop treatment with Jaypirca if you develop severe side effects.

CONTINUED ↓




**Jaypirca**<sup>®</sup>  
 pirtobrutinib 50, 100 mg  
 tablets

A Lilly Medicine

# Safety Summary (cont'd)

## Common side effects

- decreased white blood cell count
- decreased red blood cell count
- tiredness
- decreased platelet count
- decreased calcium

**These are not all the possible side effects with Jaypirca. Call your doctor for medical advice about side effects. You may report side effects at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## Before using

Before taking Jaypirca, tell your doctor about all your medical conditions, including if you:

- have an infection or have been advised that you are at increased risk of infection
- have had recent surgery or plan to have surgery. Your doctor may stop Jaypirca for a planned medical, surgical, or dental procedure
- have bleeding problems and/or are taking blood thinner medicine
- have or have had heart rhythm problems
- have high blood pressure
- have a history of other cancers, including skin cancer
- have kidney problems
- have liver problems
- are pregnant or plan to become pregnant. Jaypirca can harm your unborn baby. If you are able to become pregnant, your doctor will do a pregnancy test before starting treatment
  - Females who are able to become pregnant should use effective birth control (contraception) during treatment and for at least 1 week after the last dose of Jaypirca. Tell your doctor right away if you become pregnant or think you are pregnant during treatment
- are breastfeeding or plan to breastfeed. It is not known if Jaypirca passes into breast milk. Do not breastfeed during treatment and for at least 1 week after your final dose

**Also tell your doctor about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Jaypirca with certain other medicines may affect how Jaypirca or the other medicines work and can cause side effects.

**CONTINUED** ↓



**Jaypirca**<sup>®</sup>  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

# Safety Summary (cont'd)

## How to take

- Take Jaypirca exactly as your doctor tells you
- Do not change your dose or stop taking Jaypirca unless your healthcare provider tells you to do so
- Take Jaypirca 1 time each day at about the same time each day
- Take Jaypirca with or without food
- Swallow Jaypirca whole with water. Do not cut, crush, or chew the tablets
- If you miss a dose of Jaypirca, take it as soon as you remember on the same day. If you miss taking a dose by more than 12 hours from the time you usually take Jaypirca, skip the missed dose. Take the next dose on the next day at your usual time

## Learn more

Jaypirca is a prescription medicine. For more information, call 1-800-545-5979 or go to [www.jaypirca.lilly.com](http://www.jaypirca.lilly.com). This summary provides basic information about Jaypirca but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Jaypirca and how to take it. Your doctor is the best person to help you decide if Jaypirca is right for you.

PT CON BS CLL DEC2025



Not an actual patient.

ASK YOUR DOCTOR ABOUT JAYPIRCA

Please see [Safety Summary for Jaypirca](#) on pages 10-12.

 **Jaypirca**<sup>®</sup>  
pirtobrutinib 50, 100 mg  
tablets

A Lilly Medicine

*Lilly*

A MEDICINE COMPANY

Jaypirca<sup>®</sup> is a registered trademark and Lilly Support Services<sup>™</sup> is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.  
All other trademarks are the property of their respective owners.  
PP-PT-US-1425 12/2025 © Lilly USA, LLC 2025. All rights reserved.